Biologics Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer byJosh SandbergJuly 31, 2018
Financial Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results byJosh SandbergAugust 10, 2017
Hospitals Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria byJosh SandbergDecember 22, 2015
Recon Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences byJosh SandbergOctober 5, 2015
Recon Histogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer byJosh SandbergJuly 31, 2015
Recon Histogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer byJosh SandbergJuly 15, 2015
Spine Histogenics Corporation Announces World Class Scientific Advisory Board to Support Commercialization and Pipeline Development byJosh SandbergMay 12, 2015
